Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials

JM Llovet, J Bruix - Journal of Clinical Oncology, 2009 - ascopubs.org
Hepatocellular carcinoma (HCC) is the third largest cause of cancer-related death behind
only lung and colon cancers. 1 Overall, one third of cirrhotic patients will develop HCC …
被引用次数：37 相关文章

Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials.

JM Llovet, J Bruix - Journal of Clinical Oncology: Official Journal of …, 2009 - europepmc.org
Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II
trials. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu …

[引用][C] Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials

JM Llovet, J Bruix - … of clinical oncology: official journal of …, 2009 - pubmed.ncbi.nlm.nih.gov
Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II
trials Testing molecular therapies in hepatocellular carcinoma: the need for randomized …

[引用][C] Testing Molecular Therapies in Hepatocellular Carcinoma: The Need for Randomized Phase II Trials

JM Llovet, J Bruix - Journal of Clinical Oncology, 2009 - cir.nii.ac.jp
Testing Molecular Therapies in Hepatocellular Carcinoma: The Need for Randomized Phase
II Trials | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …